Bootstrap Example

×

The Events Calendar will be updated soon in June 2020. Please check back then.

Upcoming PGRN events

    • Fri, July 17, 2020
    • 8:00 AM - 9:00 AM (PDT)
    • ZOOM Members Only

    "Building bridges between industry, academia, health care systems and communities to advance Precision Medicine"

    Alan R. Shuldiner, MD
    Vice President
    , Regeneron Pharmaceuticals, Inc.

    • Fri, August 14, 2020
    • 8:00 AM - 9:00 AM (PDT)
    • Zoom - Members Only

    • Fri, September 11, 2020
    • 8:00 AM - 9:00 AM (PDT)
    • Zoom - Members Only


    • Fri, October 09, 2020
    • 11:00 AM - 12:00 PM (PDT)
    • Zoom - Members Only

    "Pharmacogenetics of NSAIDs: Using CYP2C9 Genotype to Guide Treatment"

    Non-steroidal anti-inflammatory drugs (NSAIDs) are some of the most commonly used drugs worldwide, but have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. Several drugs in this class are metabolized by CYP2C9, and polymorphisms in this enzyme that alter NSAID clearance may affect safety. This talk will summarize evidence supporting the association between CYP2C9 polymorphisms and NSAID exposure and discuss the recently published CPIC guidelines for usingCYP2C9 genotype to guide NSAID therapy.

    • Tue, October 27, 2020
    • 8:30 AM - 12:30 PM (PDT)
    • Zoom Virtual Meeting

    PGRN Annual Meeting - Reflections on the PGRN from Past Chairs
    Plan now to submit your abstract for the PGRN virtual poster session. Details will be announced in July.
    • Fri, November 13, 2020
    • 8:00 AM - 9:00 AM (PST)
    • Zoom - Members Only

    "Pharmacogenetics of Antidepressants in Pediatric Patients with Anxiety and Depression"
    Dr. Ramsey is the Co-Director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center, which offers pharmacogenetic tests to patients and provides interpretation of results. She will present on the
    retrospective studies of pediatric patients with pharmacogenetic test results that were treated with antidepressants. Her lab found that pharmacogenetic phenotypes were associated with response, tolerability, and length of hospitalization in children with anxiety and/or depression treated with escitalopram, sertraline, and fluoxetine. They also performed pharmacokinetic modeling of escitalopram and sertraline based on CYP2C19 phenotypes to predict doses that would provide equivalent exposure across CYP2C19 phenotypes.

     

    • Fri, December 11, 2020
    • 8:00 AM - 9:00 AM (PST)
    • Zoom - Members Only


    • Fri, January 08, 2021
    • 8:00 AM - 9:00 AM (PST)
    • Zoom - Members Only

    "Human Genetics and Drug Discovery"
    Robert Plenge, MD, PhD
    Sr. Vice President - Research & Early Development
    Bristol Myers Squibb

Copyright © 2020 the Pharmacogenomics Research Network. All Rights Reserved.

Become a member

PGRN logo
Membership dues are vital to continue the mission and work of the PGRN. Founding Members will be listed on the PGRN website. 
Powered by Wild Apricot Membership Software